news

Treeway announces Orphan Drug Designation for TW001

Posted: 1 December 2014 | | No comments yet

Treeway B.V. is pleased to announce that the European Medicines Agency has granted orphan drug designation for TW001 for the treatment of ALS…

Treeway

Treeway B.V. is pleased to announce that the European Medicines Agency (EMA) has granted orphan drug designation for TW001 for the treatment of ALS. ALS is a neurodegenerative disease causing death on average after 3 years of symptoms onset.

Treeway accelerates ALS therapy development by patients involvement and TW001 is the lead compound within Treeway’s pipeline. “Obtaining orphan designation for TW001 in the European Union (EU) is an important milestone for Treeway”, said Ronald van der Geest, Chief Development Officer for Treeway. “This orphan drug designation comes right on time to support our entry into the clinical stage, with which we are now fully engaged”.

EMA’s Orphan Medicinal Product Designation is designed to promote the development of drugs that may provide significant benefits to patients suffering from rare, life-threatening diseases. With the orphan drug designation, Treeway will benefit from several incentives related to contacts with the EMA and market exclusivity.

Related organisations